Astrazeneca (AZN) Receivables - Other (2009 - 2025)

Astrazeneca (AZN) has reported Receivables - Other for 5 consecutive years, with $2.0 billion the latest figure, recorded in Q4 2025.

• In Q4 2025, Receivables - Other rose 27.74% year-over-year to $2.0 billion; the TTM figure through Dec 2025 stood at $2.0 billion (up 27.74% YoY), while the FY2025 annual figure was $2.0 billion, up 27.74% from the prior year.
• Receivables - Other came in at $2.0 billion for Q4 2025 at Astrazeneca, up from $1.6 billion in the prior quarter.
• The five-year high for Receivables - Other was $2.0 billion in Q4 2025, with the low at $1.6 billion in Q4 2024.
• Average Receivables - Other over 5 years is $1.7 billion, with a median of $1.7 billion recorded in 2022.
• Across the five-year window, Receivables - Other fell 8.24% in 2022 and grew 27.74% in 2025, its largest moves.
• Year by year, Receivables - Other stood at $1.8 billion in 2021, then fell by 8.24% to $1.7 billion in 2022, then declined by 1.21% to $1.6 billion in 2023, then dropped by 3.66% to $1.6 billion in 2024, then grew by 27.74% to $2.0 billion in 2025.
• According to Business Quant data, Receivables - Other over the past three periods registered $2.0 billion, $1.6 billion, and $1.6 billion for Q4 2025, Q4 2024, and Q4 2023 respectively.